Aspirina e outros anti-inflamatórios não esteroidais (AINEs) devem ser usados com cuidado, especialmente em pessoas com mais de 60 anos de idade ou aquelas também medicadas com corticosteroides, bifosfonatos ou outros medicamentos antitrombóticos.[24]García Rodríguez LA, Lin KJ, Hernández-Díaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011 Mar 15;123(10):1108-15.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.110.973008
http://www.ncbi.nlm.nih.gov/pubmed/21357821?tool=bestpractice.com
[25]Knopp-Sihota JA, Cummings GG, Homik J, et al. The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study. BMC Geriatr. 2013 Apr 20;13:36.
https://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-13-36
http://www.ncbi.nlm.nih.gov/pubmed/23602075?tool=bestpractice.com
O uso simultâneo de um inibidor da bomba de prótons (IBP) demonstrou reduzir o risco de complicações gastrointestinais em pacientes aspirina e/ou anticoagulantes orais em longo prazo.[36]Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088470/?tool=pubmed
http://www.ncbi.nlm.nih.gov/pubmed/21415072?tool=bestpractice.com
[37]Kurlander JE, Barnes GD, Fisher A, et al. Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis. Am J Med. 2022 Oct;135(10):1231-1243.e8.
https://www.doi.org/10.1016/j.amjmed.2022.05.031
http://www.ncbi.nlm.nih.gov/pubmed/35679879?tool=bestpractice.com
[38]Ahn HJ, Lee SR, Choi EK, et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022 Nov;88(11):4676-87.
http://www.ncbi.nlm.nih.gov/pubmed/35921204?tool=bestpractice.com
Os IBPs previnem as úlceras pépticas e as complicações em pessoas que necessitam de terapia com AINE.[39]Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jan 25;33(6):973-80.
http://www.ncbi.nlm.nih.gov/pubmed/28076696?tool=bestpractice.com
No entanto, as diretrizes sugerem considerar uma estratégia de teste e tratamento para o Helicobacter pylori antes de iniciar a terapia em longo prazo com AINEs, uma vez que a erradicação do H pylori demonstrou proteger contra o sangramento da úlcera péptica associada à aspirina.[40]Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728-38.
http://www.ncbi.nlm.nih.gov/pubmed/19240698?tool=bestpractice.com
[41]Hawkey C, Avery A, Coupland CAC, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022 Nov 5;400(10363):1597-606.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01843-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/36335970?tool=bestpractice.com
O uso profilático de um IBP é adequado para pacientes em terapia intensiva, especialmente aqueles que precisam de ventilação mecânica, que são considerados com alto risco de sangramento gastrointestinal devido a comorbidades, como doença hepática crônica, ou que têm doenças coexistentes, como coagulopatia, sepse ou lesão renal aguda.[33]Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002 Jun;30(suppl 6):S373-8.
http://www.ncbi.nlm.nih.gov/pubmed/12072665?tool=bestpractice.com
[34]Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020 Jan 6;368:l6722.
https://www.bmj.com/content/368/bmj.l6722.long
http://www.ncbi.nlm.nih.gov/pubmed/31907223?tool=bestpractice.com
Os IBPs são geralmente aceitos como superiores aos antagonistas H2 na prevenção de hemorragia digestiva clinicamente importante em pacientes gravemente enfermos.[34]Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020 Jan 6;368:l6722.
https://www.bmj.com/content/368/bmj.l6722.long
http://www.ncbi.nlm.nih.gov/pubmed/31907223?tool=bestpractice.com
[42]Alshamsi F, Belley-Cote E, Cook D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016 May 4;20(1):120.
https://www.doi.org/10.1186/s13054-016-1305-6
http://www.ncbi.nlm.nih.gov/pubmed/27142116?tool=bestpractice.com
[43]Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med. 2017 Dec 4;44(1):1-11.
https://www.doi.org/10.1007/s00134-017-5005-8
http://www.ncbi.nlm.nih.gov/pubmed/29199388?tool=bestpractice.com
Evidências de um ensaio duplo-cego randomizado sugerem que os IBPs e antagonistas H2 têm eficácia similar na redução do risco de hemorragia digestiva alta ou úlceras em pessoas que tomam aspirina em baixas doses.[44]Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2016 Sep 15;152(1):105-10.e1.
http://www.ncbi.nlm.nih.gov/pubmed/27641510?tool=bestpractice.com
Uma metanálise que avaliou antagonistas H2, IBPs e análogos da prostaglandina constatou que os IBPs foram mais eficazes para prevenir o sangramento de úlcera que os antagonistas H2 e os análogos da prostaglandina.[45]Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-41.
https://www.doi.org/10.1016/S2468-1253(18)30037-2
http://www.ncbi.nlm.nih.gov/pubmed/29475806?tool=bestpractice.com
Os IBPs também foram mais eficazes para curar úlceras e prevenir o sangramento recorrente e a necessidade de transfusão de sangue.[45]Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-41.
https://www.doi.org/10.1016/S2468-1253(18)30037-2
http://www.ncbi.nlm.nih.gov/pubmed/29475806?tool=bestpractice.com